Genetic test to determine non-responsiveness to statin drug treatment

A method of detecting a genetic predisposition for non-responsiveness to lovastatin, pravastatin, or simvastatin treatment in a human subject with coronary artery disease, comprising:

• a) collecting a tissue sample from a human subject;
• b) amplifying nucleic acids comprising the HindIII restriction site in intron 8 of the human lipoprotein lipase gene (LPL) from said tissue sample to obtain amplification products;
• and
• c) analyzing the amplification products for the absence of a HindIII recognition site in intron 8 of the human lipoprotein lipase gene, homozygosity for an absence of said HindIII recognition site indicating a genetic predisposition in said human subject for non-responsiveness to lovastatin, pravastatin, or simvastatin treatment for coronary artery disease.

A method of detecting genetic predisposition in a CABG patient for non-responsiveness to treatment with a statin drug selected from the group consisting of lovastatin, pravastatin, and simvastatin, comprising:

• a) collecting a tissue sample from a CABG patient;
• b) amplifying nucleic acids comprising the locus of the HindIII recognition site in intron 8 of the human lipoprotein lipase (LPL) gene from said blood sample to obtain amplification products;
• and
• c) analyzing the amplification products for the absence of the HindIII recognition site in intron 8 of the human lipoprotein lipase gene, homozygosity for an absence of said HindIII recognition site indicating a genetic predisposition in said CABG patient for non-responsiveness to treatment for coronary artery disease with a statin drug selected from the group consisting of lovastatin, pravastatin, and simvastatin.

A method of detecting genetic predisposition in a CABG for non-responsiveness to treatment with lovastatin, pravastatin, or simvastatin, comprising:

• a) collecting a tissue sample from a CABG patient,
• b) amplifying nucleic acids comprising the normal locus of the HindIII recognition site in intron 8 of the human lipoprotein lipase (LPL) gene from said blood sample to obtain amplification products, by using a reverse oligonucleotide primer having the sequence 5′-GCA TCT GCC TTC AGC TAG ACA TTG-3′ (SEQ. ID. NO. 1) and a forward oligonucleotide primer having the sequence 5′-TCT TCC AGA AGG GTG AGA TTC CAA-3′ (SEQ. ID. NO. 2);
• and
• c) analyzing the amplification products for the absence of the HindIII recognition site in intron 8 of the human lipoprotein lipase gene, homozygosity for an absence of said HindIII recognition site indicating a genetic predisposition in said CABG patient for non-responsiveness to treatment for coronary artery disease with lovastatin, pravastatin, or simvastatin.

A method of detecting in a human subject a genetic predisposition for non-responsiveness to treatment for coronary artery disease with a statin drug selected from the group consisting of lovastatin, pravastatin, or simvastatin, said method comprising:

• a) collecting a tissue sample from a human subject;
• b) amplifying nucleic acids comprising the normal locus of the HindIII recognition site in intron 8 of the human lipoprotein lipase (LPL) gene from said blood sample to obtain amplification products, by using a reverse oligonucleotide primer having the sequence 5′-GCA TCT GCC TTC AGC TAG ACA TTG-3′ (SEQ. ID. NO. 1) and a forward oligonucleotide primer having the sequence 5′-TCT TCC AGA AGG GTG AGA TTC CAA-3′ (SEQ. ID. NO. 2);
• c) restricting said amplification products with HindIII;
• and
• d) analyzing the restriction fragments for the absence of the HindIII recognition site in intron 8 of the human lipoprotein lipase gene,
• wherein homozygosity for an absence of said HindIII recognition site indicates a genetic predisposition for non-responsiveness to treatment for coronary artery disease with a statin drug selected from the group consisting of lovastatin, pravastatin, or simvastatin.

A method of detecting a genetic predisposition in a human subject for non-responsiveness to treatment with a statin drug selected from the group consisting of lovastatin, pravastatin, or simvastatin, said method comprising:

• a) collecting a tissue sample from a human subject;
• b) amplifying nucleic acids comprising the normal locus of the (TTTA)n tetranucleotide repeat sequence in intron 6 of the human lipoprotein lipase gene (LPL) from said tissue sample to obtain amplification products;
• and
• c) analyzing the amplification products for (TTTA)n tetranucleotide repeat alleles present in said nucleic acids, homozygosity for a (TTTA)n 4 allele indicating a genetic predisposition for non-responsiveness to treatment for coronary artery disease with a statin drug selected from the group consisting of lovastatin, pravastatin, or simvastatin.